Description
Anti-EPHA3 Antibody, Non-Fucosylated (BioBet-217ZP) is a humanized monoclonal IgG1, κ antibody against EPHA3. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Myelodysplastic syndrome, Myelofibrosis, Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced EPHA3 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Background
This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene encodes a protein that binds ephrin-A ligands. Two alternatively spliced transcript variants have been described for this gene. [provided by RefSeq, Jul 2008]
Alternative Names
Ephrin receptor A3; EPH receptor A3; ephrin type-A receptor 3; tyrosine protein kinase TYR04; tyrosine-protein kinase receptor REK4; ETK; ETK1; HEK; HEK4
Cellular Localization
Plasma membrane, Extracellular region or secreted
Involvement in Disease
Diseases associated with EPHA3 include Lung Large Cell Carcinoma and Adenocarcinoma.
Related Pathways
Its related pathways are Guidance Cues and Growth Cone Motility and Activation of cAMP-Dependent PKA.
Function
Receptor tyrosine kinases, which bind to ephrin family ligands that reside on the cell membranes of neighboring cells, resulting in contact-dependent bidirectional signaling to neighboring cells. The signal pathway downstream of the receptor is called the forward signal, and the signal pathway downstream of the ephrin ligand is called the reverse signal. For ephrin-A ligand, it preferentially binds EFNA5. The activation of EFNA5 can regulate cell adhesion, cytoskeletal organization and cell migration. Probably through the activation of EFNA1, it participates in the migration and differentiation of cardiomyocytes, and regulates the formation of atrioventricular ducts and ventricular septum during development. Participate in the optic tectal mapping of neurons. It is also possible to control the separation, but not to direct the development of motor and sensory axons in neuromuscular circuits.
Post-translational modifications
Autophosphorylates upon activation by EFNA5. Phosphorylation on Tyr-602 mediates interaction with NCK1. Dephosphorylated by PTPN1.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-217ZP
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to EPHA3. Fibatuzumab is a human monoclonal antibody that can be potentially used in the treatment of Myelodysplastic syndrome, Myelofibrosis, Cancer.
Antibody Indication
Myelodysplastic syndrome, Myelofibrosis, Cancer
